GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2007

Unigene Inks Supply Deal With Novartis

  • Unigene Laboratories will receive $2.5 million to supply Novartis with specified quantities of a bulk peptide necessary for development of its osteoporosis treatment.

    Unigene will develop a process for the peptide, and Novartis will have the opportunity to purchase additional quantities as necessary.

    In 2004, Novartis exclusively licensed Unigene's technology to manufacture another peptide, calcitonin, and it now runs the scaled-up process at its manufacturing facility in Kundl, Austria.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »